A Vaccine Formulated With a Combination of TLR-2 and TLR-9 Adjuvants and the Recombinant Major Outer Membrane Protein Elicits a Robust Immune Response and Significant Protection Against a Chlamydia Muridarum Challenge
Microbes and Infection - United States
doi 10.1016/j.micinf.2013.11.009
Full Text
Open PDFAbstract
Available in full text
Date
March 1, 2014
Authors
Publisher
Elsevier BV